Panelists discuss how to approach treatment selection and sequencing for a 58-year-old woman with high-risk multiple myeloma (MM) who has developed progressive disease after stem cell transplantation, considering factors such as prior therapy exposure, available options, and disease biology.
Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss potential strategies that teams can implement to ensure clinical trials are more representative of the general population.
Panelists discuss decision-making in metastatic non–-small cell lung cancer (NSCLC) when molecular testing results are delayed, focusing on strategies to optimize treatment while awaiting results.
Panelists discuss the role of molecular testing in metastatic non–-small cell lung cancer (NSCLC), emphasizing its importance in identifying actionable mutations and guiding personalized treatment strategies.
Alan Tan, MD, discusses upcoming trials that could change the landscape of frontline and adjuvant renal cell carcinoma therapy.
Mariam F. Eskander, MD, MPH, and Coral O. Omene, MD, PhD, discuss which populations are seen as the most underrepresented in oncology clinical trials.
Saeed Sadeghi, MD, discusses treatment options in low-risk myelodysplastic syndrome at a Case-Based Roundtable event.
Noah S. Kalman, MD, MBA, discusses the evolving role of molecular and genetic testing in thyroid cancer management.
The panelist discusses how, when discussing first-line treatment decisions for cancer patients, healthcare professionals primarily consider patient-specific factors like disease stage, molecular profile, comorbidities, and performance status. When discussing options with high-risk patients, healthcare professionals typically take a shared decision-making approach, thoroughly explaining both potential benefits and side effect management strategies. These conversations weigh factors like quality-of-life impact, monitoring requirements, and individual patient preferences to arrive at an optimal treatment strategy.
Panelists discuss how; the patient case presents a 47-Year-Old Woman with EGFR-mutated Advanced/Metastatic NSCLC. The patient presents to her primary care physician (PCP) with continued dry cough, dyspnea, and weight loss. She has a history of hypertension, previously managed on an ACE inhibitor, but is now on atenolol.
Panelists discuss how clinical trial data inform the selection of second-line therapies for patients with myelofibrosis, focusing on response assessment criteria and identifying optimal candidates for various treatment options.
Panelists discuss how myelofibrosis can evolve following initial treatment, examining common patterns of disease progression and strategies for adapting therapeutic approaches based on individual patient response and changing clinical parameters.
Savita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, and SBRT in metastatic castration-sensitive prostate cancer.
Arnab Basu, MD, MPH, FACP, discusses circulating tumor DNA (ctDNA) tests with high sensitivity and specificity.
Cyrus M. Khan, MD, discusses how treatment paradigms for chronic lymphocytic leukemia have changed in recent years, particularly regarding frontline therapy options.
Panelists discuss how to optimize maintenance therapy following autologous stem cell transplantation by evaluating factors such as duration, drug selection, and risk-adapted approaches to maximize long-term outcomes in multiple myeloma patients.
Panelists discuss how the paradigm in transplant-eligible newly diagnosed multiple myeloma (NDMM) has shifted to considering which patients should not receive quadruplet CD38-containing regimens rather than who should, given the compelling efficacy data supporting this approach.
David Sallman, MD, discusses using eprenetapopt and azacitidine in TP53-mutant myelodysplastic syndrome and acute myeloid leukemia post-allogeneic stem cell transplantation.
Experts discuss an overview of the STARTER-NET study, emphasizing its goals, key outcomes, and potential impact on clinical practice.
Experts discuss an overview of the ALASCCA study, highlighting its objectives, results, and clinical implications.
Experts discuss the CheckMate 8HW study, focusing on its design, key findings, and impact on treatment strategies.
Experts discuss an overview of the BREAKWATER study, highlighting its key objectives, findings, and implications.
Ann LaCasce, MD, MMSc, director of the Dana-Farber/Massachusetts General Brigham Fellowship in Hematology/Oncology, highlights the role of bispecific antibodies in lymphoma research.
Marwan G. Fakih, MD, explains the implications of the findings from the phase 2 trial of balstilimab plus botensilimab for the treatment of patients with microsatellite stable metastatic colorectal cancer without liver metastases.
Panelists discuss how the landmark COMFORT trials have shaped the understanding of Janus kinase inhibitor therapy response criteria and long-term clinical outcomes in patients with myelofibrosis, providing crucial data to inform current treatment approaches.
The panelist discusses how for managing patients with R/R multiple myeloma, community clinicians should focus on personalized treatment approaches, incorporating novel therapies such as CAR T-cell therapy while carefully monitoring for and managing toxicities through established protocols. Key considerations include implementing systematic toxicity management strategies, maintaining long-term patient monitoring, and staying informed about emerging therapeutic options. The field is evolving with promising novel agents and combination approaches being investigated, particularly for patients who progress after initial treatments.
Panelists discuss how risk stratification tools and patient-specific factors guide treatment selection and timing of interventions for patients with newly diagnosed intermediate 2–risk myelofibrosis, with a focus on optimizing clinical outcomes.
Marwan G. Fakih, MD, provides an overview of the study design, rationale, and findings from a phase 2 trial of balstilimab with botensilimab for the treatment of patients with microsatellite stable metastatic colorectal cancer without liver metastases.
Ashraf Z. Badros, MB, ChB, discusses the next steps following the phase 3 AURIGA trial of daratumumab and lenalidomide vs lenalidomide maintenance in patients with newly diagnosed multiple myeloma.
David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.